Three dimensional conformal radiotherapy / intensity modulated radiotherapy alone vs three dimensional conformal therapy / intensity modulated radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A phase III randomized study

Trial Profile

Three dimensional conformal radiotherapy / intensity modulated radiotherapy alone vs three dimensional conformal therapy / intensity modulated radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A phase III randomized study

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Bicalutamide (Primary) ; Goserelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jun 2009 New source identified and integrated (United Kingdom Clinical Research Network recprd no. 871).
    • 03 Jun 2009 Planned number of patients changed from 800 to 820 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top